- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05128318
TuLip : Role of the Tumor Environment in Cancer-related Fat Loss (TuLip)
Study of the Tumor-adipose Tissue Dialogue: Role of Tumor Acidosis in the Induction of Adipocyte Lipolysis
Cancer cachexia is defined as a weight loss of more than 5% over the last 6 months, a loss of body fat and muscle atrophy. It is found in 80% of patients with advanced cancer. In this context, white adipose tissue is a particularly interesting target since its depletion precedes the loss of muscle mass, and is sufficient to induce a decrease in the response to anti-cancer treatments and in the survival of patients.
This cachexia is associated with advanced tumors that present acidosis and metastasis. In this clinical study the investigators would like explore the acid environment effect on the human adipose tissue depletion and more specifically on adipocyte lipolysis.
The main objective of the "TuLip" clinical study is therefore to validate in human subcutaneous and visceral adipocytes that factors secreted by tumor cells cultivated in acid tumor environment stimulate the release of lipids from adipose tissue. Adipocytes retrieves from this study will also be used to validate identified potential lipolytic factors derived from these cells.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brussel, Belgium, 1200
- Cliniques Universitaires Saint Luc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Programmed surgeries in the abdominal area in the Department of Surgery and Transplantation at Cliniques Universitaires Saint-Luc under the supervision of Prof. Dr. Benoit Navez.
- Hospitalization in the context of surgery
- Caucasian
- Age between 18 and 60 years (included).
- Body mass index less than 30 and greater than or equal to 18.5
- Programmed Nissen fundoplication (to treat hiatal hernia and gastroesophageal reflux) or cholecystectomy (to treat vesicular lithiasis), eventration, or parietal surgery .
- Adults capable of expressing their wishes.
- Understanding French
Exclusion Criteria:
- Body mass index below 18.5 and above 30.
- Patients with cancer, infection, autoimmune or inflammatory disease, metabolic syndrome.
- Patients with beta-blockers, hypoglycemics, anti-diabetics, hypolipidemics.
- Adults unable to express their will.
- Not understanding French
- Patients participating in a clinical trial for a drug treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients with BMI < 30 kg/m2
Collection of subcutaneous and visceral adipose tissue pieces of 1-2 cm3 during abdominal surgery procedures
|
Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis.
During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the lipolytic response of adipocytes isolated from human visceral and subcutaneous adipose tissue to factors derived from cancer cells in acid environment by the glycerol measurement
Time Frame: Up to 100 days after the adipose tissue collection"
|
Measure ex-vivo of the lipolysis of subcutaneous and visceral adipocytes in the presence of factors derived from cancer cells.
The lipolysis will be assessed by the measure of glycerol (in mol/L) released by adipocytes.
|
Up to 100 days after the adipose tissue collection"
|
|
Evaluation of the lipolytic response of adipocytes isolated from human visceral and subcutaneous adipose tissue to factors derived from cancer cells in acid environment by the fatty acid measurement.
Time Frame: Up to 100 days after the adipose tissue collection"
|
Measure ex-vivo of the lipolysis of subcutaneous and visceral adipocytes in the presence of factors derived from cancer cells.
The lipolysis will be assessed by the measure of free fatty acids (in mol/L) released by adipocytes.
|
Up to 100 days after the adipose tissue collection"
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by western-blot
Time Frame: Up to 2 years after the adipose tissue collection
|
Protein analyses by western-blot (arbitrary units).
|
Up to 2 years after the adipose tissue collection
|
|
Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by ELISA
Time Frame: Up to 2 years after the adipose tissue collection
|
Protein analyses by ELISA (mol/L or g/L).
|
Up to 2 years after the adipose tissue collection
|
|
Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by proteomic analyses
Time Frame: Up to 2 years after the adipose tissue collection
|
Protein analyses via proteomic analyses (relative units).
|
Up to 2 years after the adipose tissue collection
|
|
Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by biochemical analyses
Time Frame: Up to 2 years after the adipose tissue collection
|
Biochemical analyses (biochemical kits)
|
Up to 2 years after the adipose tissue collection
|
|
Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by metabolomic analyses
Time Frame: Up to 2 years after the adipose tissue collection
|
Metabolomic analyses (arbitrary units or mol/L)
|
Up to 2 years after the adipose tissue collection
|
|
Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by RNA sequencing
Time Frame: Up to 2 years after the adipose tissue collection
|
Measurement of gene expression by RNA sequencing (in counts) of RNA extracted from these ex-vivo cultured human adipocytes.
|
Up to 2 years after the adipose tissue collection
|
|
Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by RT-qPCR
Time Frame: Up to 2 years after the adipose tissue collection
|
Measurement of gene expression by RT-qPCR (in relative units) of RNA extracted from these ex-vivo cultured human adipocytes.
|
Up to 2 years after the adipose tissue collection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Benoit Navez, Professor, Cliniques Universitaires Saint-Luc
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TuLip
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Yale UniversityNational Institute of Nursing Research (NINR); The Glimpse Group IncRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
University of Michigan Rogel Cancer CenterCompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Atrium Health Wake Forest BaptistRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
Vanderbilt-Ingram Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Second Affiliated Hospital of Soochow UniversityNot yet recruitingCancer | Solid Cancer
-
New Mexico Cancer Research AllianceOhio State University Comprehensive Cancer Center; H. Lee Moffitt Cancer Center...RecruitingCancer | Cancer RiskUnited States
-
Children's Hospital of PhiladelphiaCompletedCancer | Childhood CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
UNICANCERRecruitingAdvanced Breast Cancer | Advanced Gastric Cancer | Advanced Urothelial Cancer | Advanced Non Small Cell Lung Cancer (NSCLC)France
Clinical Trials on Nissen Fundoplication, cholecystectomy
-
Turku University HospitalCompleted
-
Grubnik VolodymyrCompletedGastro Oesophageal Reflux Disease
-
Implantica CE Reflux Ltd.RecruitingGastroesophageal Reflux Disease (GERD)Switzerland, Norway, Italy, Germany
-
Kuopio University HospitalRecruitingRecurrence | Hiatal Hernia | Paraesophageal HerniaFinland
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux | Idiopathic Pulmonary FibrosisUnited States
-
University of UtahCompletedNervous System Diseases | Gastroesophageal Reflux | Enteral Nutrition | FundoplicationUnited States
-
Federal University of São PauloHospital State PublicCompletedGastroesophageal RefluxBrazil
-
Johns Hopkins UniversityCompletedGastroesophageal RefluxUnited States
-
Institute of Child HealthCompletedGastro-Oesophageal RefluxUnited Kingdom
-
Implantica CE Reflux Ltd.Not yet recruitingGERD (Gastroesophageal Reflux Disease)Germany, Austria, Switzerland